Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2022 16:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
June 28, 2022 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

In vitro studies determined that SBP-101 reduced cellular viability across a broad range of cancer cell types, with an exceptionally strong reduction in ovarian adenocarcinoma viability resulting in a...
June 16, 2022 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.

MINNEAPOLIS, June 16, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today...
May 12, 2022 16:05 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q1 2022 Financial Results

MINNEAPOLIS, May 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today...
April 27, 2022 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela to Host Virtual R&D Day

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
April 26, 2022 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results

MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
April 12, 2022 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Poster Presentation at American Association for Cancer Research:

MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
March 24, 2022 16:05 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer,...
March 23, 2022 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET

MINNEAPOLIS, March 23, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
March 10, 2022 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela to Participate in the 34th Annual Roth Conference

MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...